Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.35 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 9/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15835022 | 0.89 | NPC1 (0.41) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL9994310 | 0.88 | GRM5 (0.40) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL19852990 | 0.85 | POLB (0.35) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL14239096 | 0.85 | POLB (0.35) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL15818228 | 0.84 | GRM5 (0.36) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL19846643 | 0.84 | POLB (0.34) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL20755816 | 0.84 | GRM5 (0.37) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL14239094 | 0.83 | POLB (0.34) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL6923322 | 0.82 | GRM5 (0.39) | NPC1HCRTR1RAB9APOLBPTPN7 | |
| SCHEMBL14239419 | 0.82 | GRM5 (0.35) | NPC1HCRTR1RAB9APOLBPTPN7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | SUNOVION PHARAMCEUTICALS INC. | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037585-A1 | METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF | GRM5, GRIK5, GRM2 | NPC1 1799/4885HCRTR1 185/4885RAB9A 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.